← Patent-cliff monitor small molecule SOVALDI SOFOSBUVIR
Loss of exclusivity June 2031 latest FDA-listed patent expiry
Drug detail Brand name SOVALDI Active ingredient SOFOSBUVIR Strength 200MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval August 2019 Marketing status RX
Listed patents Patent Expires Type 8618076*PED June 2031 — 9284342*PED March 2031 — 8618076 December 2030 substance, product 9284342 September 2030 substance, product 7964580*PED September 2029 — 8889159*PED September 2029 — 8633309*PED September 2029 — 8889159 March 2029 product 7964580 March 2029 substance, product 8633309 March 2029 substance, product 8580765*PED September 2028 — 9085573*PED September 2028 — 8334270*PED September 2028 — 8580765 March 2028 substance, product 8334270 March 2028 substance, product 9085573 March 2028 substance, product
Regulatory exclusivity Code Expires ODE* August 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.